Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | $15.00 → $10.00 | Outperform → Market Perform | Leerink Partners |
| 4/12/2024 | $21.00 | Buy | BTIG Research |
| 1/8/2024 | Outperform → In-line | Evercore ISI | |
| 5/23/2022 | $12.00 | Outperform | SVB Leerink |
| 3/2/2022 | $10.00 → $11.00 | Underweight | Morgan Stanley |
| 2/24/2022 | $8.00 → $12.00 | Buy | HC Wainwright & Co. |
| 11/5/2021 | $7.00 → $12.00 | Underweight → Neutral | JP Morgan |
| 9/16/2021 | $14.00 → $10.00 | Underweight | Morgan Stanley |
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma Theravance Biopharma, Inc.'s focus is to
Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm
DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.c
Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a
Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire
DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Mama’s Creations Inc (NASDAQ:MAMA) fell in today's pre-market trading following first-quarter results. Mama's Creations posted downbeat earnings for its first quarter, while sales topped estimates. Mama’s Creations shares declined 3% to $6.97 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. U-BX Technology Ltd. (NASDAQ:UBXG) shares dipped 15.4% to $9.83 in pre-market trading after jumping 21% on Tuesday. Ferrovial SE (NASDAQ:FER) shares declined 5.8% to $38.99 in pre-market trading after gaining 5% on
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $20 price target.
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
4 - Theravance Biopharma, Inc. (0001583107) (Issuer)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
SC 13G/A - Theravance Biopharma, Inc. (0001583107) (Subject)
Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously
BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00
Evercore ISI downgraded Theravance Biopharma from Outperform to In-line
Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm
DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.c
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approvedNow expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months laterQ2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024Q2 2024 ending cash balance of $96.1 millionDUBLIN, Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced
10-Q - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)
8-K - Theravance Biopharma, Inc. (0001583107) (Filer)